{
  "id": 15740548,
  "title": "Hype vs. reality: What pharma’s hottest R&D bets have actually proved",
  "url": "https://urgent.news/2026/10/20/hype-vs-reality-what-pharmas-hottest-r-d-bets-have-actually-proved",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-20T12:00:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/pharma-rd-bets-clinical-proof-gsk-summit/833332/"
  },
  "original_language": "en",
  "account": null,
  "summary": "New types of bispecifics, antibod-drug conjugates and cell therapies haven’t yet themselves in the clinic. Pharmaceutical companies are betting billions anyway.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}